IONS — Ionis Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $4.51bn
- $3.46bn
- $705.14m
- 51
- 10
- 60
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.67 | ||
| Price to Tang. Book | 7.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.4 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.63% | ||
| Return on Equity | -93.1% | ||
| Operating Margin | -67.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 729.26 | 810.46 | 587.37 | 787.65 | 705.14 | 660.43 | 842.96 | -8.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Directors
- Joseph Loscalzo CHM (69)
- Brett Monia CEO (59)
- Elizabeth Hougen CFO (59)
- C. Frank Bennett EVP (64)
- Patrick O'Neil EVP (47)
- Onaiza Cadoret-Manier EVP (57)
- Richard Geary EVP (63)
- Eugene Schneider EVP (48)
- Eric Swayze EVP (55)
- B. Lynne Parshall OTH (66)
- Joseph Baroldi OTH (43)
- Joseph Wender LED (76)
- Allene Diaz DRC (57)
- Spencer Berthelsen IND (68)
- Michael Hayden IND (69)
- Joan Herman IND (67)
- Joseph Klein IND (59)
- Frederick Muto IND (67)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 25th, 1991
- Public Since
- May 17th, 1991
- No. of Shareholders
- 447
- No. of Employees
- 1,069
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 158,964,772
- Address
- 2855 Gazelle Court, CARLSBAD, 92010
- Web
- https://www.ionis.com/
- Phone
- +1 7609319200
- Auditors
- Ernst & Young LLP
Upcoming Events for IONS
Q1 2025 Ionis Pharmaceuticals Inc Earnings Call
Ionis Pharmaceuticals Inc at Bank of America Global Healthcare Conference
Ionis Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference
Ionis Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Ionis Pharmaceuticals Inc Earnings Release
Similar to IONS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Ionis Pharmaceuticals share price?
As of Today at 21:22 UTC, shares in Ionis Pharmaceuticals are trading at $28.40. This share price information is delayed by 15 minutes.
How has the Ionis Pharmaceuticals share price performed this year?
Shares in Ionis Pharmaceuticals last closed at $28.40 and the price had moved by -30.58% over the past 365 days. In terms of relative price strength the Ionis Pharmaceuticals share price has underperformed the S&P500 Index by -34.72% over the past year.
What are the analyst and broker recommendations for Ionis Pharmaceuticals?
The overall consensus recommendation for Ionis Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ionis Pharmaceuticals dividend yield?
Ionis Pharmaceuticals does not currently pay a dividend.
Does Ionis Pharmaceuticals pay a dividend?
Ionis Pharmaceuticals does not currently pay a dividend.
When does Ionis Pharmaceuticals next pay dividends?
Ionis Pharmaceuticals does not currently pay a dividend.
How do I buy Ionis Pharmaceuticals shares?
To buy shares in Ionis Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ionis Pharmaceuticals?
As of the previous close price of $28.40, shares in Ionis Pharmaceuticals had a market capitalisation of $4.51bn.
Where are Ionis Pharmaceuticals shares listed?
Here are the trading details for Ionis Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IONS
What kind of share is Ionis Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Ionis Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ionis Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Ionis Pharmaceuticals is $58.04. That is 104.37% above the last closing price of $28.40.
Analysts covering Ionis Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$3.82 for the next financial year.
Find out moreWhat is the trend in the Ionis Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ionis Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -20.69%.
As of the last closing price of $28.40, shares in Ionis Pharmaceuticals were trading -25.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ionis Pharmaceuticals PE Ratio?
The Ionis Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $28.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ionis Pharmaceuticals?
Ionis Pharmaceuticals' management team is headed by:
- Joseph Loscalzo - CHM
- Brett Monia - CEO
- Elizabeth Hougen - CFO
- C. Frank Bennett - EVP
- Patrick O'Neil - EVP
- Onaiza Cadoret-Manier - EVP
- Richard Geary - EVP
- Eugene Schneider - EVP
- Eric Swayze - EVP
- B. Lynne Parshall - OTH
- Joseph Baroldi - OTH
- Joseph Wender - LED
- Allene Diaz - DRC
- Spencer Berthelsen - IND
- Michael Hayden - IND
- Joan Herman - IND
- Joseph Klein - IND
- Frederick Muto - IND